CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2052-A |

# Specialty Guideline Management Elaprase

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Elaprase | idursulfase |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Elaprase is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Elaprase has been shown to improve walking capacity in patients 5 years and older.

In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with Elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of Elaprase have not been established in pediatric patients less than 16 months of age.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* Initial requests: iduronate-2-sulfatase enzyme assay or genetic testing results supporting diagnosis.
* Continuation requests: chart notes documenting a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

## Coverage Criteria

### Mucopolysaccharidosis II (MPS II, Hunter syndrome)1,2

Authorization of 12 months may be granted for treatment of MPS II (Hunter syndrome) when the diagnosis of MPS II was confirmed by enzyme assay demonstrating a deficiency of iduronate-2-sulfatase enzyme activity or by genetic testing.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who have a clinically positive response to therapy, which shall include improvement, stabilization, or slowing of disease progression.

## References

1. Elaprase [package insert]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; September 2021.
2. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009;124(6):e1228-e1239.